

Depending on the type of alpha-AR blockage used in combination with dutasteride, there is a difference in serum PSA decrease rate and prostate volume reduction rate.

Magari T, Kano N, Ogura H, Kurosawa I

Department of Urology, Kurosawa Hospital, Takasaki, Japan

Introduction


Dutasteride (DUT) reduces prostate volume and improves LUTS by releasing the mechanical obstruction in the prostatic urethra. This drug is often used with alpha-AR blockage different in action mechanism. Several kinds of alpha-AR blockage is used, however the report that compared the effect every drug has not been published as far as our knowledge. The report that Inhibit prostate cancer cell growth by several alpha-AR blockage has been published 1,2), however, there are very few reports that naftopidil inhibit prostate growth in BPH patients³). Therefore effect may vary according to a combination drug. In this report, we examined changes of the prostate volume (PV), residual urine volume (RU), and serum PSA levels using DUT and several kinds of alpha-AR blockage to the patients, complaining of LUTS associated with BPH.

Materials and methods

We included for 316 cases diagnosed BPH and performed combination therapy with DUT and alpha-AR blockage. DUT 0.5mg was administered once a day for over 12 months continuously. We divided alpha-AR blockage into tamsulosin (TAM), naftopidil (NAF), silodosin (SIL), and we compared the effect. We examined changes of the prostate volume (PV), post void residual (PVR), and serum PSA levels using DUT and several kinds of alpha-AR blockage to the patients.

Results

Fig. 1 Changes of the serum PSA levels



The rate of change of serum PSA in each groups were -47.8 ± 18.4 , -45.1 ± 61.0 , and $-50.4 \pm 56.0\%$ ($p < 0.001$) at 6M, and -33.9 ± 45.8 , -61.0 ± 10.4 , and $-56.0 \pm 20.0\%$ ($p < 0.001$) at 12M, respectively. Compared with TAM, NAF and SIL were significantly decreased ($p < 0.01$) at 12M (Fig. 1).

Tomohiro Magari

ICS 2017
FLORENCE

I have no financial conflicts of interest to disclose concerning the presentation.

Conclusions

- ✓ This is the first report to examine the changes not only PV but also serum PSA values by combination therapy with DUT and alpha-AR blockage, particularly comparison of the effect several kinds of alpha-AR blockage.
- ✓ In this study, it was suggested that the difference in PSA decrease rate and prostate volume reduction rate may be different depending on alpha-AR blockage used in combination.
- ✓ In the future, prospective and randomize examination seemed to be necessary for strict comparison.

Table. 1 :Background of alpha-AR blockage use case


	TAM	NAF	SIL
n	45	59	212
age	79(54-97)	76(56-93)	74(53-96)
PSA	3.0(0.5-21.1)	3.7(0.2-31.7)	4.6(0.2-28.9)
PV	55.2(28.2-131.1)	52.0(24.2-124.8)	59.9(21.8-129.7)
PVR	19.9(0-180.2)	24.0(0-249.0)	80.0(0-252.0)

Median (range)

PSA : Serum PSA (ng/mL) , PV : Prostate Volume (mL) , PVR : Post Void Residual (mL)


Background of alpha-AR blockage use case was shown Table.1. Compared with TAM and NAF, SIL significantly increased PVR ($p < 0.01$).

Fig. 2 Changes of the prostate volume



The rate of change of PV in each groups were -21.9 ± 17.7 , -10.8 ± 15.7 , and $-14.7 \pm 14.5\%$ ($p < 0.001$) at 3M, and -24.2 ± 16.3 , -15.3 ± 15.2 , and $-18.6 \pm 16.1\%$ ($p < 0.001$) at 6M, and -33.6 ± 15.6 , -23.8 ± 16.5 , and $-25.6 \pm 15.4\%$ ($p < 0.001$) at 12M, respectively. Compared with NAF, TAM was significantly decreased ($p < 0.05$) at 3, 6, and 12M, and compared with SIL, TAM was significantly decreased ($p < 0.05$) at 3 and 12M (Fig. 2).

Fig. 3 Changes of the post void residual



PVR in each groups were discussed in the rate of change from the baseline, 9.4 ± 127.8 , 29.7 ± 163.3 , and 45.6 ± 316.0 at 3M, and 22.3 ± 129.0 , 23.8 ± 123.6 , and $18.0 \pm 219.5\%$ at 6M, and 12.0 ± 177.4 , 0.47 ± 134.8 , and $-5.8 \pm 126.1\%$ at 12M, respectively. No significant difference was noted at 3, 6, and 12M among TAM, NAF, and SIL. (Fig. 3).